These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 30431391

  • 1. Comparative study of the binding mode between cytochrome P450 17A1 and prostate cancer drugs in the absence of haem iron.
    Song D, Zhang J, Wang Y, Hu J, Xu S, Xu Y, Shen H, Wen X, Sun Z.
    J Biomol Struct Dyn; 2019 Oct; 37(16):4161-4170. PubMed ID: 30431391
    [Abstract] [Full Text] [Related]

  • 2. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
    DeVore NM, Scott EE.
    Nature; 2012 Jan 22; 482(7383):116-9. PubMed ID: 22266943
    [Abstract] [Full Text] [Related]

  • 3. Comparisons of Prostate Cancer Inhibitors Abiraterone and TOK-001 Binding with CYP17A1 through Molecular Dynamics.
    Xiao F, Yang M, Xu Y, Vongsangnak W.
    Comput Struct Biotechnol J; 2015 Jan 22; 13():520-7. PubMed ID: 26682016
    [Abstract] [Full Text] [Related]

  • 4. Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1.
    Petrunak EM, Rogers SA, Aubé J, Scott EE.
    Drug Metab Dispos; 2017 Jun 22; 45(6):635-645. PubMed ID: 28373265
    [Abstract] [Full Text] [Related]

  • 5. Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site.
    Petrunak EM, Bart AG, Peng HM, Auchus RJ, Scott EE.
    J Biol Chem; 2023 Mar 22; 299(3):102999. PubMed ID: 36773804
    [Abstract] [Full Text] [Related]

  • 6. New steroidal oxazolines, benzoxazoles and benzimidazoles related to abiraterone and galeterone.
    Latysheva AS, Zolottsev VA, Veselovsky AV, Scherbakov KA, Morozevich GE, Pokrovsky VS, Novikov RA, Timofeev VP, Tkachev YV, Misharin AY.
    Steroids; 2020 Jan 22; 153():108534. PubMed ID: 31678134
    [Abstract] [Full Text] [Related]

  • 7. Interaction of 17α-hydroxylase, 17(20)-lyase (CYP17A1) inhibitors - abiraterone and galeterone - with human sterol 14α-demethylase (CYP51A1).
    Masamrekh R, Kuzikov A, Veselovsky A, Toropygin I, Shkel T, Strushkevich N, Gilep A, Usanov S, Archakov A, Shumyantseva V.
    J Inorg Biochem; 2018 Sep 22; 186():24-33. PubMed ID: 29807244
    [Abstract] [Full Text] [Related]

  • 8. Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2.
    Fehl C, Vogt CD, Yadav R, Li K, Scott EE, Aubé J.
    J Med Chem; 2018 Jun 14; 61(11):4946-4960. PubMed ID: 29792703
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.
    Bruno RD, Vasaitis TS, Gediya LK, Purushottamachar P, Godbole AM, Ates-Alagoz Z, Brodie AM, Njar VC.
    Steroids; 2011 Nov 14; 76(12):1268-79. PubMed ID: 21729712
    [Abstract] [Full Text] [Related]

  • 10. Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors.
    Bonomo S, Hansen CH, Petrunak EM, Scott EE, Styrishave B, Jørgensen FS, Olsen L.
    Sci Rep; 2016 Jul 12; 6():29468. PubMed ID: 27406023
    [Abstract] [Full Text] [Related]

  • 11. CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2.
    Malikova J, Brixius-Anderko S, Udhane SS, Parween S, Dick B, Bernhardt R, Pandey AV.
    J Steroid Biochem Mol Biol; 2017 Nov 12; 174():192-200. PubMed ID: 28893623
    [Abstract] [Full Text] [Related]

  • 12. Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.
    Cheong EJY, Nair PC, Neo RWY, Tu HT, Lin F, Chiong E, Esuvaranathan K, Fan H, Szmulewitz RZ, Peer CJ, Figg WD, Chai CLL, Miners JO, Chan ECY.
    J Pharmacol Exp Ther; 2020 Sep 12; 374(3):438-451. PubMed ID: 32554434
    [Abstract] [Full Text] [Related]

  • 13. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells.
    Soifer HS, Souleimanian N, Wu S, Voskresenskiy AM, Collak FK, Cinar B, Stein CA.
    J Biol Chem; 2012 Feb 03; 287(6):3777-87. PubMed ID: 22174412
    [Abstract] [Full Text] [Related]

  • 14. Hedgehog Proteins Consume Steroidal CYP17A1 Antagonists: Potential Therapeutic Significance in Advanced Prostate Cancer.
    Bordeau BM, Ciulla DA, Callahan BP.
    ChemMedChem; 2016 Sep 20; 11(18):1983-6. PubMed ID: 27435344
    [Abstract] [Full Text] [Related]

  • 15. Abiraterone and D4, 3-keto Abiraterone binding to CYP17A1, a structural comparison study by molecular dynamic simulation.
    Mehralitabar H, Ghasemi AS, Gholizadeh J.
    Steroids; 2021 Mar 20; 167():108799. PubMed ID: 33465380
    [Abstract] [Full Text] [Related]

  • 16. Illuminating cytochrome P450 binding: Ru(ii)-caged inhibitors of CYP17A1.
    Li A, Yadav R, White JK, Herroon MK, Callahan BP, Podgorski I, Turro C, Scott EE, Kodanko JJ.
    Chem Commun (Camb); 2017 Mar 28; 53(26):3673-3676. PubMed ID: 28304025
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pregnenolonyl-α-glucoside exhibits marked anti-cancer and CYP17A1 enzymatic inhibitory activities.
    Chou FP, Hsu WC, Huang SC, Chang CY, Chiou YS, Tsai CT, Lyu JW, Chen WT, Wu TK.
    Chem Commun (Camb); 2020 Feb 06; 56(11):1733-1736. PubMed ID: 31938799
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.